Antithrombotic Management After PCI in Patients Requiring Oral Anticoagulation

1. Initial Triple Therapy and Early Aspirin Discontinuation

• In patients undergoing PCI who also need oral anticoagulation, triple therapy should be limited to the first 30 days; aspirin is the agent to discontinue, after which dual therapy (oral anticoagulant + P2Y12 inhibitor) is continued. American College of Cardiology recommendation, Class I, Level A. 1, 2
• The default post‑PCI strategy for most anticoagulated patients is to stop aspirin at hospital discharge or within 1 week and maintain dual therapy (OAC + clopidogrel). American College of Cardiology, Class I, Level A. 1, 2
• For patients at standard or high bleeding risk, aspirin cessation at discharge or within 1 week is advised. American College of Cardiology, Class I, Level A. 1
• In patients with high ischemic risk and low bleeding risk, extending aspirin up to 30 days may be considered. American College of Cardiology, Class IIa, Level B. 3
• Prolonging triple therapy beyond 30 days is not recommended for the majority of patients. European Society of Cardiology, Class I, Level A. 3, 4

2. Choice of Agents for Dual Therapy

• Oral anticoagulant: Direct oral anticoagulants (DOACs) are preferred over warfarin because they consistently lower bleeding without compromising efficacy. American College of Cardiology, Class I, Level A. 3, 1, 5
• P2Y12 inhibitor: Clopidogrel is the preferred agent over prasugrel or ticagrelor due to a more favorable bleeding profile. American College of Cardiology, Class I, Level A. 3, 1, 2

3. Duration of Dual Therapy

4. Evidence Supporting Early Aspirin Cessation

• Randomized trials (WOEST, PIONEER AF‑PCI, RE‑DUAL PCI, AUGUSTUS, ENTRUST‑AF PCI) demonstrated that dual therapy markedly reduces major bleeding compared with triple therapy. American College of Cardiology, Class I, Level A. 1, 2, 5
• The same trials showed no significant increase in ischemic events (e.g., myocardial infarction, stent thrombosis) with dual therapy. American College of Cardiology, Class I, Level A. 1, 2
• However, these trials were not powered to detect differences in thrombotic outcomes, so efficacy conclusions are limited. American College of Cardiology, Class IIb, Level B. 1

5. High Ischemic‑Risk Features That May Justify Extending Aspirin to 30 Days

• Acute coronary syndrome presentation. American College of Cardiology, Class IIa, Level B. 3
• Complex procedural/anatomic characteristics (e.g., bifurcation lesions, multiple stents). American College of Cardiology, Class IIa, Level B. 3, 2
• Prior stent thrombosis. American College of Cardiology, Class IIa, Level B. 2
• Incomplete revascularization. American College of Cardiology, Class IIa, Level B. 2
• These extensions are only appropriate when the patient also has a low bleeding risk. American College of Cardiology, Class IIa, Level B. 3, 1

6. Post‑PCI Management Algorithm

30 Days After PCI

• Stop aspirin (if not already stopped). American College of Cardiology, Class I, Level A. 1
• Continue oral anticoagulant + clopidogrel (dual therapy). American College of Cardiology, Class I, Level A. 1, 2

6 Months After PCI

• Low ischemic risk / high bleeding risk: Discontinue clopidogrel; maintain oral anticoagulant alone. American College of Cardiology, Class I, Level A. 3, 1
• Standard risk: Continue dual therapy until 12 months. American College of Cardiology, Class I, Level A. 3, 1

12 Months After PCI

• Most patients: Stop clopidogrel; continue full‑dose oral anticoagulant for stroke prevention. American College of Cardiology, Class I, Level A. 3, 1
• Selected high ischemic‑risk patients: Consider extending clopidogrel beyond 12 months. American College of Cardiology, Class IIa, Level B. 3, 1

7. Specific DOAC Dosing Guidance

• When rivaroxaban is used in combination therapy, a reduced dose of 15 mg once daily is acceptable; after antiplatelet therapy is stopped, the dose should be increased to 20 mg once daily for stroke prevention. American College of Cardiology, Class I, Level A. 3, 6

8. Bleeding‑Risk Mitigation Measures (Mandatory for All Patients on Combined Therapy)

• Proton‑pump inhibitor (PPI): Routine use reduces gastrointestinal bleeding. American College of Cardiology, Class I, Level A. 1, 5
• Low‑dose aspirin (≤100 mg/day) if aspirin is used: Minimizes bleeding risk. American College of Cardiology, Class I, Level A. 3, 1, 2

9. Common Pitfalls to Avoid

• Do not extend triple therapy beyond 6 months; the highest bleeding risk occurs in the first 30 days and outweighs coronary event risk thereafter. European Society of Cardiology, Class I, Level A. 5, 4
• Avoid prasugrel or ticagrelor in triple therapy; clopidogrel remains the preferred P2Y12 inhibitor for its lower bleeding risk. American College of Cardiology, Class I, Level A. 3, 1, 2
• After stopping antiplatelet therapy, ensure rivaroxaban is up‑titrated to the full therapeutic dose. American College of Cardiology, Class I, Level A. 3
• Do not omit PPI prophylaxis in any patient receiving combined antithrombotic therapy. European Society of Cardiology, Class I, Level A. 5

Antithrombotic Therapy After PCI

Introduction to Anticoagulation Strategies

• The American College of Cardiology recommends switching from warfarin to a direct oral anticoagulant (DOAC) post-PCI whenever possible, as DOACs demonstrate consistent bleeding reduction compared to warfarin without compromising efficacy 7, 8, 9, 10
• For patients requiring warfarin after PCI, the American Heart Association suggests immediately transitioning to double therapy (oral anticoagulant plus P2Y12 inhibitor, preferably clopidogrel) at hospital discharge, discontinuing aspirin within 1-4 weeks in most patients 7, 11, 8

Peri-PCI Antithrombotic Regimen

• Administer aspirin plus P2Y12 inhibitor (clopidogrel preferred) during the immediate peri-PCI phase through hospital discharge, as recommended by the American College of Cardiology 7, 11
• Clopidogrel remains the P2Y12 inhibitor of choice over prasugrel or ticagrelor when combined with oral anticoagulation due to lower bleeding risk, according to the American Heart Association 7, 9
• Resume oral anticoagulation within 24 hours post-PCI in most patients after assessing hemostasis at the access site, as suggested by the American College of Cardiology 8, 10

Post-Discharge Antithrombotic Regimen

• Discontinue aspirin at hospital discharge or within 1 week and continue double therapy (oral anticoagulant + clopidogrel 75 mg daily), as recommended by the American College of Cardiology 7, 11, 8
• Extend aspirin (81 mg daily) for up to 1 month only in highly selected patients with high ischemic/thrombotic risk, low bleeding risk, and acceptable bleeding risk tolerance, according to the American Heart Association 7, 11, 8

Duration of P2Y12 Inhibitor Therapy

• Discontinue P2Y12 inhibitor at 6 months post-PCI in patients with high bleeding risk or low ischemic risk, as suggested by the American College of Cardiology 7, 9
• Continue P2Y12 inhibitor for 12 months in standard risk patients, according to the American Heart Association 7, 9
• May reasonably continue P2Y12 inhibitor beyond 12 months in patients with high ischemic risk and low bleeding risk, as recommended by the American College of Cardiology 7, 9

After P2Y12 Inhibitor Discontinuation

• Continue oral anticoagulation monotherapy at full stroke-prevention doses indefinitely, as suggested by the American Heart Association 7, 9
• If using rivaroxaban at the reduced dose tested in trials, increase to the full FDA-approved dose once antiplatelet therapy stops, according to the American College of Cardiology 7, 8, 10

Critical Warfarin-Specific Considerations

• Consider bridging with parenteral anticoagulation only in high thromboembolic risk patients until INR reaches therapeutic range, as recommended by the American College of Cardiology 8, 10
• Monitor INR closely as the combination of warfarin with antiplatelet agents substantially increases bleeding risk, according to the American Heart Association 12

Bleeding Risk Mitigation

• Add a proton pump inhibitor in all patients receiving combined anticoagulation and antiplatelet therapy to reduce gastrointestinal bleeding risk, as suggested by the American College of Cardiology 13
• Use radial access for PCI when feasible to minimize vascular complications, according to the American Heart Association 8, 10